Oral oncology最新文献

{"title":"PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.","authors":"Glenn J. Hanna ,&nbsp;Dandan Zheng ,&nbsp;Wei Gao ,&nbsp;Gleicy M. Hair ,&nbsp;Lei Ai ,&nbsp;Yan Song ,&nbsp;Nati Lerman ,&nbsp;Behzad Bidadi ,&nbsp;Abigail Zion ,&nbsp;Lin Zou ,&nbsp;Yuexin Tang ,&nbsp;Liya Wang ,&nbsp;Sanjay Merchant ,&nbsp;Christopher M. Black","doi":"10.1016/j.oraloncology.2024.107146","DOIUrl":"10.1016/j.oraloncology.2024.107146","url":null,"abstract":"<div><h3>Background</h3><div>Pembrolizumab with/without platinum + 5-FU is approved for the first-line (1L) treatment of R/M HNSCC, and its monotherapy use requires PD-L1 Combined Positive Score (CPS) ≥ 1. We aimed to understand PD-L1 testing patterns and associations with patient characteristics and treatment choice in R/M HNSCC.</div></div><div><h3>Methods</h3><div>Adults with R/M HNSCC initiating 1L systemic therapy were included from a U.S. nationwide database primarily compromised of community practices (07/01/2019–12/31/2023). PD-L1 testing patterns, treatment sequence, and time gaps related to testing and treatment initiation were summarized. Logistic regression was used to test associations between patient characteristics and PD-L1 testing patterns, and between CPS scores and 1L pembrolizumab monotherapy use.</div></div><div><h3>Results</h3><div>Of 2,207 patients, 32.7 % received PD-L1 testing before 1L therapy initiation, 17.4 % after 1L therapy initiation, and 50.0 % were never tested. Most patients (55.9 %) who tested positive before 1L therapy received pembrolizumab monotherapy while those who tested negative received pembrolizumab + platinum + 5-FU most commonly (31.6 %). Among patients untested before 1L therapy, the most common 1L treatment was pembrolizumab monotherapy (24.3 %). Patients with an ECOG ≥ 2 had higher odds of being tested before 1L therapy (OR: 1.42, p &lt; 0.01). CPS scores were associated with higher odds of receiving 1L pembrolizumab monotherapy (OR: 4.11 and 4.96 for CPS 1–19 and ≥ 20, respectively; both p &lt; 0.0001).</div></div><div><h3>Conclusions</h3><div>This study revealed low utilization of PD-L1 testing to guide treatment choice and impactful gaps between specimen collection, the receipt of results, and 1L therapy initiation. There is a need to improve clinician awareness of the importance of PD-L1 testing and an opportunity for updated guidelines on testing.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107146"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From infection to immortality: The role of HPV and telomerase in head and neck cancer","authors":"Silvia Giunco ,&nbsp;Annarosa Del Mistro ,&nbsp;Marzia Morello ,&nbsp;Jacopo Lidonnici ,&nbsp;Helena Frayle ,&nbsp;Silvia Gori ,&nbsp;Anita De Rossi ,&nbsp;Paolo Boscolo-Rizzo","doi":"10.1016/j.oraloncology.2024.107169","DOIUrl":"10.1016/j.oraloncology.2024.107169","url":null,"abstract":"<div><div>Head and neck squamous cell carcinomas (HNSCCs) represent a heterogeneous group of malignancies with multifactorial aetiologies. High-risk human papillomavirus (hrHPV) infections, particularly HPV16, and the dysregulation of telomerase activity, specifically through its catalytic subunit, telomerase reverse transcriptase (TERT) are among the key contributors to HNSCC development and progression. HPV promotes oncogenesis via the E6 and E7 oncoproteins, which inactivate tumour suppressors TP53 and RB1, leading to unchecked cellular proliferation. Concurrently, telomerase activation plays a critical role in HNSCC by maintaining telomere length, thus enabling cellular immortality, and facilitating tumour development and progression. The interplay between HPV and telomerase is significant; HPV oncoprotein E6 enhances telomerase activity through multiple regulatory mechanisms, including upregulating TERT expression. Beyond telomere maintenance, TERT influences signalling pathways, cellular metabolism, and the tumour microenvironment, contributing to aggressive tumour behaviour and poor prognosis. This review integrates the roles of HPV and telomerase in HNSCC, focusing on their molecular mechanisms and interactions that drive carcinogenesis and influence disease progression. Understanding the synergistic effects of HPV and TERT in HNSCC may be crucial for risk stratification, prognostic assessment, and the development of novel therapeutic strategies targeting these specific molecular pathways.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107169"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma”","authors":"Sukran Senyurek ,&nbsp;Nulifer Kilic Durankus ,&nbsp;Ugur Selek ,&nbsp;Erkan Topkan","doi":"10.1016/j.oraloncology.2025.107177","DOIUrl":"10.1016/j.oraloncology.2025.107177","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107177"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142952711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anaplastic thyroid carcinoma in a 43-year-old female confirmed by metastatic lymph node pathology: A case report","authors":"Huanyu Jiang,&nbsp;Lijuan Zhou,&nbsp;Teng Zhao,&nbsp;Gang Zou,&nbsp;Lili Lv,&nbsp;Zhenkun Yu","doi":"10.1016/j.oraloncology.2025.107192","DOIUrl":"10.1016/j.oraloncology.2025.107192","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107192"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do we recognize oral oncology with accuracy? AI-driven models serve in the diagnosis of oral squamous cell carcinoma","authors":"Jiayi Chen","doi":"10.1016/j.oraloncology.2025.107194","DOIUrl":"10.1016/j.oraloncology.2025.107194","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107194"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of extracranial schwannoma in the masticator space removed by endoscopic assisted transoral approach (EATA)","authors":"Giovanni Motta ,&nbsp;Pasquale Puzone ,&nbsp;Gino Latini ,&nbsp;Arianna Di Stadio ,&nbsp;Luca D’Ascanio","doi":"10.1016/j.oraloncology.2024.107164","DOIUrl":"10.1016/j.oraloncology.2024.107164","url":null,"abstract":"<div><h3>Background</h3><div>Extracranial schwannomas, particularly those arising from the masticator space, are rare entities. Given the challenges in pre-operative diagnosis and the potential for misdiagnosis, accurate localization and differential diagnosis are crucial for optimal surgical planning.</div></div><div><h3>Case Report</h3><div>A 42-year-old woman underwent a head and neck MRI for unrelated reasons and was incidentally found to have a mass in the left masticator space. Radiological findings were suggestive of a schwannoma. An endoscopic-assisted transoral approach was adopted for the resection of the lesion. Histopathological examination confirmed the diagnosis of schwannoma. The patient had an uneventful postoperative recovery.</div></div><div><h3>Conclusion</h3><div>This case report highlights the feasibility of an endoscopic-assisted transoral approach for the resection of rare masticator space schwannomas. This minimally invasive technique offers potential benefits in terms of reduced morbidity and improved cosmetic outcomes.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107164"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142966392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional and oncological outcomes of transoral laser versus robotic surgery in supraglottic squamous cell carcinoma","authors":"Charlotte Loubieres ,&nbsp;Robin Baudouin ,&nbsp;Marta Circiu ,&nbsp;Florent Couineau ,&nbsp;Lise Crevier-Buchman ,&nbsp;Tiffany Rigal ,&nbsp;Clémence Forges ,&nbsp;Aude Julien-Laferriere ,&nbsp;Grégoire Vialatte De Pemille ,&nbsp;Jérôme R. Lechien ,&nbsp;Stéphane Hans","doi":"10.1016/j.oraloncology.2025.107178","DOIUrl":"10.1016/j.oraloncology.2025.107178","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the surgical, functional and oncological outcomes of Transoral Laser Microsurgery (TLM) and Transoral Robotic Surgery (TORS) for the treatment of supraglottic squamous cell carcinoma.</div><div>Study Design:</div><div>Retrospective case series with prospective data.</div><div>Settings:</div><div>Tertiary Academic Medical Center.</div></div><div><h3>Methods</h3><div>A chart-review analysis, with prospective follow-up was performed on 122 patients treated for a supraglottic squamous cell carcinoma with either TLM or TORS between 2003 and 2019. Patients were grouped according to the surgical technique used. Clinical, surgical, functional and oncological outcomes were compared, including local and regional controls, DFS, and OS, and postoperative complications.</div></div><div><h3>Results</h3><div>A total of 122 patients, including 47 treated with TLM and 75 with TORS. Negative margins were observed in n = 12/47 (25.5 %) of TLM cases and n = 4/75 (5.3 %) of TORS cases (<em>p</em> &lt; 0.05). There was no significant difference between the two techniques in terms of 5-year local and regional control, however a significant difference was found in disease-free survival and overall survival. The functional laryngeal preservation rate was 97.8 % in the TLM group and 100 % in the TORS group.</div></div><div><h3>Conclusion</h3><div>Both techniques appear to be safe and effective, though TORS shows superiority in achieving negative margins compared to TLM. Therefore, the choice of technique should be tailored to available resources, surgical team preferences, and experience, while also considering the learning curves associated with each approach.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107178"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142966394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyalinising parotid adenoid cystic carcinoma with dystrophic calcification masquerading as a thyroid-like carcinoma","authors":"Bacem K. Othman,&nbsp;Wafaey Badawy","doi":"10.1016/j.oraloncology.2024.107163","DOIUrl":"10.1016/j.oraloncology.2024.107163","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107163"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143104955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scapula or Fibula?: Prospective data-driven decision criteria for flap selection in mandibular reconstruction planning","authors":"Maharshi Panchal ,&nbsp;Katrina Zaraska ,&nbsp;Thomas D. Milner ,&nbsp;Khanh Linh Tran ,&nbsp;Antony Hodgson ,&nbsp;Sidney Fels ,&nbsp;James Scott Durham ,&nbsp;Eitan Prisman","doi":"10.1016/j.oraloncology.2025.107190","DOIUrl":"10.1016/j.oraloncology.2025.107190","url":null,"abstract":"<div><h3>Objectives</h3><div>The objectives of the study are twofold: 1) to propose a set of criteria for virtually evaluating different types of reconstructions for mandibular defects during surgical planning, and 2) to prospectively apply the criteria to a series of mandibular reconstructions to select the optimal flap.</div></div><div><h3>Materials and Methods</h3><div>Clinically relevant assessment criteria were selected, including volumetric overlap, Haussdorf-95, bony contact, ramus/symphysis angles, and dental implantability. In 2021, 21 consecutive patients undergoing mandibular reconstructions were consented to the study. For each patient, seven virtual reconstructions were created: vertical scapula, horizontal scapula, 1-segment fibula, optimal fibula determined by the Ramer-Douglas-Peucker (RDP) algorithm, RDP + 1 fibula, and RDP-1 fibula. The surgeon selected the optimal reconstruction for each patient based on the objective criteria and clinical considerations.</div></div><div><h3>Results</h3><div>The vertical scapula was selected for 12 cases, the RDP fibula for 6 cases, and the horizontal scapula for 3 cases. For defects involving the symphysis, the horizontal scapula was the frequently selected as its geometry could be leveraged to recreate the symphysis angle. For the remaining defects, the RDP fibula optimizes the bony contact, performs well in volume overlap, and is the most implantable. The vertical scapula minimizes osteotomies while maximizing each criterion but results in low implantability. On average, the chosen reconstruction performed better on all criteria compared to the remaining proposed models.</div></div><div><h3>Conclusion</h3><div>The criteria proposed comprises of measurable and clinically important metrics that can serve as a useful tool for reconstructive surgeons in selecting the optimal flap for mandibular reconstruction.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"162 ","pages":"Article 107190"},"PeriodicalIF":4.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is postoperative adjuvant therapy necessary for pT3N0 oral cavity squamous cell carcinoma?","authors":"Chun-Hung Hua ,&nbsp;Jin-Ching Lin ,&nbsp;Yu-Wen Wen ,&nbsp;Chung-Jan Kang ,&nbsp;Chien-Yu Lin ,&nbsp;Hsiu-Ying Ku ,&nbsp;Kang-Hsing Fan ,&nbsp;Shu-Hang Ng ,&nbsp;Shu-Ru Lee ,&nbsp;Yao-Te Tsai ,&nbsp;Wen-Cheng Chen ,&nbsp;Li-Yu Lee ,&nbsp;Chih-Yen Chien ,&nbsp;Cheng Ping Wang ,&nbsp;Tsung-Ming Che ,&nbsp;Shyuang-Der Terng ,&nbsp;Chi-Ying Tsai ,&nbsp;Hung-Ming Wang ,&nbsp;Chia-Hsun Hsieh ,&nbsp;Chih-Hua Yeh ,&nbsp;Chun-Ta Liao","doi":"10.1016/j.oraloncology.2025.107198","DOIUrl":"10.1016/j.oraloncology.2025.107198","url":null,"abstract":"<div><h3>Background</h3><div>The current NCCN guidelines advocate for the use of adjuvant radiotherapy (RT) or chemoradiotherapy (CRT) in pT3N0 oral cavity squamous cell carcinoma (OCSCC). Here, we sought to evaluate whether postoperative RT/CRT may confer a survival advantage in pT3N0 patients who lack adverse pathological features.</div></div><div><h3>Methods</h3><div>A dataset of 852 pT3N0 OCSCC patients treated between 2018 and 2021 was analyzed. Patients with adverse pathological features (i.e., positive margins, margins &lt;5 mm, lymphovascular invasion, or perineural invasion) were excluded, leaving 235 eligible patients. The cohort was further refined by omitting 12 patients who received surgery plus chemotherapy and two cases who received RT doses &lt;5000 cGy, resulting in two study groups: surgery alone (n = 131) and surgery plus RT/CRT (n = 90).</div></div><div><h3>Results</h3><div>Baseline characteristics were comparable between groups, except for a higher proportion of buccal subsite (<em>p</em> = 0.0063) and female patients (<em>p</em> = 0.0495) in the surgery alone group. Kaplan-Meier analyses revealed no significant differences in 4-year disease-specific survival (DSS) (84.2 % <em>versus</em> 85.9 %, <em>p</em> = 0.8834) or overall survival (OS) (75.6 % <em>versus</em> 84.8 %, <em>p</em> = 0.2376). These findings were confirmed by multivariable analyses and remained consistent after propensity score matching (n = 74 per group), with similar survival outcomes between groups (4-year DSS, 90.7 % <em>versus</em> 83.2 %, <em>p</em> = 0.4020; 4-year OS, 87.0 % <em>versus</em> 81.9 %, <em>p</em> = 0.6121)</div></div><div><h3>Conclusions</h3><div>For patients with pT3N0 OCSCC lacking adverse pathological features, the addition of adjuvant RT/CRT does not appear to confer a survival benefit over surgery alone.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"162 ","pages":"Article 107198"},"PeriodicalIF":4.0,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}